Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute for Health and Care Excellence ruled that the drug was not a cost-effective treatment for skin cancer.
The Association of the British Pharmaceutical Industry (ABPI) and the British Lung Foundation (BLF) have launched a new working party tasked with producing a new national five-year prevention, diagnosis and treatment plan for lung health.
More than 90 percent of health and care leaders across England say they are “concerned” about their organisation's ability to cope with demand this winter, with the majority (63 percent) citing “extreme” concern.
Pfizer says it is considering the future of its massive consumer health division, with options including a full or partial separation of the business through a spin-off, sale or other transaction, or keeping hold of the unit.
Eli Lilly’s breast cancer drug Verzenio has failed to improve overall survival in a late-stage study assessing the drug’s potential in patients with KRAS-mutated, advanced non-small lung cancer (NSCLC).
Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome, a rare genetic lipid disorder.
AstraZeneca’s Tagrisso has been awarded breakthrough status in the US as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC), potentially speeding up its development and regulatory pathway.